glycyl-L-prolyl-L-arginylsarcosine are potent inhibitors of fibrin polymerization. Moreover, these peptides have a natural stability stemming from their inherent resistance to proteolysis because of the involvement of imino acids in each of their peptide bonds. The peptide glycyl-L-prolylL-arginyl-L-proline binds to fibrinogen and to fragment D, in both cases with an association constant of approximately 5 X 104; it does not bind to fragment E. The number of binding sites is two for fibrinogen and one for fragment D. The tripeptide lycyl-L-prolyl-L-arginine binds less tightly and is less than ha f as effective in preventing polymerization. The peptide glycyl-L-histidyl-L-arginyl-L-proline, which corresponds exactly to the amino terminus of the-fibrin a-chain, does not inhibit the aggregation of fibrin monomers under the conditions used. It does bind weakly to fibrinogen, however, suggesting the involvement of sites other than those binding the a-chain analogues. Various other peptides were found not to inhibit polymerization; these included glycine-L-proline, L-prolyl-L-arginine and glycyl-L-prolyl-Lseryl-L-proline. The last-named corresponds to the serine/arginine amino acid replacement previously reported for a defective human fibrinogen. Vertebrate fibrinogen is transformed into fibrin by the thrombin-catalyzed release of small polar peptides from the amino termini of the a-and i-chains (1 
The last-named tetrapeptides are of particular interest because one corresponds to the amino terminus of the fibrin ,8-chain and the other, to the amino acid replacement (serine for arginine) reported for the defective human fibrinogen variant known as fibrinogen Detroit (8) .
MATERIALS AND METHODS
Human blood plasma was obtained from the San Diego Blood Bank and fibrinogen prepared according to a previously described procedure (9) . Fragments D and E were prepared by plasmin digestion of fibrinogen followed by DEAE chromatography along the lines originally described by Nussenzweig et al. (10) . A complete description of the digestion and separation conditions appears in a previous article from this laboratory (11). Fibrin monomers were prepared by dispersing fibrin in 1 M NaBr/0.05 M Na acetate, pH 5.3 (12) . In this regard, human fibrinogen (10-15 mg/ml) was clotted with bovine thrombin (Parke-Davis, 1 unit/ml final conc.); the final solution contained 150 mM NaCl, 1 mM EDTA, and 2.5 mM phosphate, pH 7 .0. After the clot had been allowed to form at room temperature for approximately 30 min, it was wound out on a glass rod and dispersed in a minimal volume of the sodium bromide solution. The dispersion was continued with gentle stirring for 8 hr. at which point it was centrifuged to remove any undispersed material. The A2o of the dispersed fibrin preparations (fibrin monomers) was generally about 17 (11 mg/ml). Reaggregation of the fibrin was effected by adding 25 Al of the fibrin monomer preparation to 0.5 ml of 80 mM phosphate buffer, pH 6.3 , in a 1-cm path-length cuvette. The solution was mixed immediately and reaggregation was monitored by measuring the scattered light in a Zeiss spectrophotometer at 350 nm (13) . Peptide additives were present in the phosphate buffer in advance of the addition of fibrin monomers. The additives included peptides we synthesized ourselves as well as some other commercially prepared peptides used as controls.
Peptide Synthesis. Solid-phase peptide synthesis was conducted by established Merrifield procedures (14, 15) , and a complete description, including materials, yields, etc., will appear elsewhere. In essence, however, the appropriate Bocamino acids (Boc-proline, Boc-nitroarginine, and Boc-sarcosine) were refluxed (in ethanol containing triethylamine) with chloromethylated polystyrene resin (Bio-Rad); the degree of substitution attained was generally about 0.4 No. 8 Visking dialysis tubing. In the case of fibrinogen binding studies, 1 .0 ml of fibrinogen solution (10 mg/ml) was dialyzed against 5 ml of a solution containing 0.2 M NaCl, 0.05 M phosphate buffer (pH 7.0), and various concentrations of the radioactive peptide under study. Binding studies with fragments D and E were performed similarly except that the protein concentration was reduced to 5 mg/ml. These latter studies were confined to the peptide glycyl-L-prolyl-L-arginyl-L-proline; in this case a bovine plasma albumin (10 mg/ml) control was also performed simultaneously. After 8 hr equilibration at room temperature, the dialysis bags were cut open and 0.5 ml aliquots of the inside and outside solutions were removed for scintillation counting 
RESULTS
Thrombin/Fibrinogen Clotting Assays. The peptides Gly-Pro-Arg-Sar, Gly-Pro-Arg-Pro, and Gly-Pro-Arg all exhibited significant inhibition of clotting in that they prevented or slowed the appearance of fibrin gels when added as a component of thrombin/fibrinogen mixtures (Table 1) . Under the conditions used (fibrinogen = 1.5 mg/ml), the most effective peptides, Gly-Pro-Arg-Pro and Gly-Pro-Arg-Sar, completely prevented clotting at concentrations of about 10-3 M, and, even at 10-4 M, gel formation was significantly delayed. Gly-Pro-Arg exhibited significantly weaker inhibitory action. The inhibition of clotting is likely due in fact to an inhibition of fibrin polymerization.
Fibrin Monomer Reaggregation Studies. Gly-Pro-Arg-Sar t Various peptide concentrations were studied; see Fig. 1 . Other ineffective peptides tested in this system included Gly-Leu-Tyr, Ala-Pro-Gly, tosyl-Arg-Sar-methylester (16), glycylglycine ethylester, and glycine ethylester.
All peptides (except Pro-Arg) were labeled with [14C]glycine; see Fig.   2 and Table 2 .
and Gly-Pro-Arg-Pro both proved to be powerful inhibitors of fibrin monomer reaggregation. Moreover, the effectiveness of the inhibition depended on both the concentration of the peptide inhibitor and the fibrin monomer concentration. In order to completely prevent polymerization, an approximately 100-fold molar excess of peptide to fibrin monomer was required, although significant retardation of polymerization occurred at ratios as low as 20:1 (these ratios allow for the fact that the fibrin "monomer" is actually dimeric). The peptide Gly-Pro-Arg proved to be less than half as effective as the tetrapeptides used (Fig. 1) , and the dipeptides Gly-Pro and Pro-Arg had no detectable effect. Various unrelated peptides and amino acid derivatives (Table 1 ) and the tetrapeptides Gly-His-Arg-Pro and Gly-Pro-Ser-Pro also had no effect. Gly-His-Arg-Pro is the sequence found at the amino terminus of the fibrin 3-chain, and Gly-Pro-Ser-Pro was modeled on the amino acid replacement that has been reported for the variant human fibrinogen known as fibrinogen Detroit (8) . As in the case of the defective fibrinogen, substitution of the arginine residue by serine completely obliterated its effectiveness. Equilibrium Dialysis Studies. Radioactive Gly-Pro-Arg-Pro was found to bind to human fibrinogen with an association constant of about 4 X 104 (Fig. 2) . The number of sites at saturation extrapolated to two per 340,000 Mr. The peptide did not bind detectably to a preparation of bovine plasma albumin (10 mg/ml) run simultaneously. The tripeptide Gly-Pro-Arg bound less than half as tightly, but it also indicated the presence of two binding sites per fibrinogen molecule. Radioactive glycine, Gly-Pro, and Gly-Pro-Ser-Pro did not exhibit any binding under similar conditions (Table 1) . Gly-His-Arg-Pro bound with an association constant of only 9 X 103 at pH 7.0, and the binding dropped off to less than half that at pH 6.5 
DISCUSSION
The tripeptidyl sequence Gly-Pro-Arg has endured at the amino terminus of fibrin a-chains for more than 400 million yr, being present in the fibrin of the most primitive vertebrates extant (19) as well as in mammalian fibrin (Table 2 ). This persistence is altogether consistent with a strategic structure-function interdependence. Moreover, replacement of the arginine residue with a serine at this position has been reported in the case of a defective human fibrinogen (8), the polymerization of which is impaired (22) . Both of these observations-the one evolutionary and the other genetic-are consistent with early notions that the newly exposed amino terminus ought to be involved in some kind of intermolecular association leading to fibrin polymerization. In formulating the experiments described in this report, we visualized the unmasked sequence as a simple knob which could become involved in a knob-hole interaction. In undertaking the syntheses, we added a fourth residue, because in the natural situation the peptide chain continues on its course, and because the presence of a free carboxyl group might offset the effect of the positively charged arginine side chain. We Plots of binding data from various equilibrium dialysis studies in which radioactive peptides Gly-Pro-Arg-Pro (A), Gly-Pro-Arg (x), and Gly-His-Arg-Pro (0) were exposed to fibrinogen (see also Table 1 ). R = moles of bound peptide/mole of fibrinogen; C = concentration of peptide. Fibrinogen concentration = 11 mg/ml (3.2 x 10-2mM).
been reported to be cleaved by thrombin (23) and by plasmin (24) , however, convinced us to incorporate secondary amino acids (imino-) at this position in order to prevent undesirable proteolysis during our experiments. It also did not escape our attention that these compounds have potential therapeutic value as antipolymerants, and long-term stability and invulnerability to proteases would obviously be advantageous in such a setting.
Previous reports from this laboratory have dealt with the effectiveness of the Arg-Sar bond in peptides designed as thrombin inhibitors (16) . As a result, we realized that the synthetic tetrapeptides reported in this article could have antithrombin activity independent of the fibrin antipolymerant action. As a consequence we turned to fibrin monomer reaggregation studies in order to evaluate their effectiveness. Thus, Gly-Pro-Arg ought not to be a thrombin inhibitor per se, because it not only has an unprotected carboxyl group but is itself a product of thrombin cleavage. Ironically, Gly-Pro-Arg has been synthesized by others in the past and reported to be a thrombin inhibitor (25) . The thrombin plasma assay used by those workers obviously precluded their discovering its actual mode of action, its "anti-thrombin" effect most likely being entirely due to the inhibition of fibrin polymerization.
The observation that the peptides which inhibit fibrin polymerization bind to fragment D was consistent with the proposed scheme whereby a reciprocal association occurs between the central and terminal domains of neighboring molecules (7). It is also consistent with experiments in which fibrinogen and fragment D can be absorbed to immobilized fibrin (26) .
The fact that the tetrapeptide Gly-His-Arg-Pro, which corresponds to the terminal sequence exposed on the E-chain of fibrin, does not impair fibrin reaggregation is especially interesting, although the data have to be carefully considered. First, it must be remarked that technical difficulties make fibrin reaggregation studies difficult above pH6. 5 . Under the conditions of our study (pH 6.3) , the histidine was presumably protonated. In line with this, the binding of Gly-His-Arg-Pro to fibrinogen was significantly less at pH 6.5 than at pH 7 .0 or 7.3. On the other hand, Gly-His-Arg-Pro had no effect on the clotting time in the thrombin/fibrinogen assays conducted at pH 7.3 , suggesting that the binding involves a set of sites that are different from those that are involved in initial polymerization. Although further binding and competition studies ought to resolve this point, the present observations are consistent with the well-known fact that fibrin polymerization in mammals can occur after release of the fibrinopeptide A only (27, 28) .
The strength of the association of the tetrapeptides GlyPro-Arg-Sar and Gly-Pro-Arg-Pro with fibrinogen is sufficient to ensure that affinity labeling studies (29) using similar compounds with functional reactive groups attached are feasible. It will be of great'interest to learn which portions of the individual chains are involved in the actual sites. Also of interest will be studies with lamprey fibrinogen because that material can be clotted by the exclusive removal of the fibrinopeptide B (19, 30 
